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Abstract
Background: Since 1999 GHESKIO, a large voluntary counseling and HIV testing center in Port-au-Prince, Haiti, has had an
ongoing collaboration with the Haitian Ministry of Health to reduce the rate of mother to child HIV transmission. There are
limited data on the ability to administer complex regimens for reducing mother to child transmission and on risk factors for
continued transmission and infant mortality within programmatic settings in developing countries.
Methods and Findings: We analyzed data from 551 infants born to HIV-infected mothers seen at GHESKIO, between 1999
and 2005. HIV-infected mothers and their infants were given ‘‘short-course’’ monotherapy with antiretrovirals for
prophylaxis; and, since 2003, highly active antiretroviral therapy (HAART) when clinical or laboratory indications were met.
Infected women seen in the pre-treatment era had 27% transmission rates, falling to 10% in this cohort of 551 infants, and
to only 1.9% in infants of women on HAART. Mortality rate after HAART introduction (0.12 per year of follow-up [0.08–0.16])
was significantly lower than the period before the availability of such therapy (0.23 [0.16–0.30], P,0.0001). The effects of
maternal health, infant feeding, completeness of prophylaxis, and birth weight on mortality and transmission were
determined using univariate and multivariate analysis. Infant HIV-1 infection and low birth weight were associated with
infant mortality in less than 15 month olds in multivariate analysis.
Conclusions: Our findings demonstrate success in prevention of mother-to-child HIV transmission and mortality in a highly
resource constrained setting. Elements contributing to programmatic success include provision of HAART in the context of a
comprehensive program with pre and postnatal care for both mother and infant.
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Introduction
In 2007, 420,000 human immunodeficiency virus type 1 (HIV)
infections are estimated to have occurred in children as a result of
mother to child transmission (MTCT) during pregnancy (intra-
uterine), during birth (intra-partum) or from breastfeeding [1].
The vast majority of such infections occurred in low and middle-
income countries [1].
In high income countries, MTCT is now rare (,2%) due to
universal use of highly active antiretroviral therapy (HAART) for
pregnant women, elective caesarean sections and avoidance of
breastfeeding [2–4]. The standard of care in lower income
countries have been simplified, generally shorter, and less
expensive regimens [5–11]. These regimens have included
primarily single dose nevaripine (sdNVP) or short course regimens
comprised of single or two drugs administered at the later stages of
pregnancy [5–11]. The ultimate efficacy of these regimens maybe
reduced in breastfeeding populations due to postnatal transmission
[12]. Currently the World Health Organization (WHO) recom-
mends a two-tiered approach for prevention of MTCT (PMTCT)
in low income countries that includes provision of HAART for
HIV-infected pregnant women in need of therapy for their own
health to supplement the simplified regimens. However, the data
on safety and effectiveness of HAART for PMTCT largely stems
from experiences in higher income countries. There have been few
reports that have assessed the impact of HAART in further
reducing MTCT in high HIV seroprevalence and resource-limited
settings [13].
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3723Haiti has the highest prevalence of HIV (2.2%) of any nation
outside of sub-Saharan Africa [14]. The Groupe Haı ¨tien d’E ´tudes du
Sarcome de Kaposi et des Infections Opportunistes (GHESKIO) located in
Port-au-Prince is the largest voluntary counseling and testing
center (VCT) for HIV in Haiti. In 1999, in collaboration with the
Haitian Ministry of Health, GHESKIO established a program
whose goals were to reduce the rate of MTCT and decrease
mortality in infants born to HIV-infected mothers. The standard
of care in Haiti for PMTCT was a shortened course of zidovudine
during the latter stages of pregnancy (scZDV) for HIV infected
pregnant women and for their infants from March 1999 until early
2003[8,9]. With the availability of HAART in 2003, the program
shifted to a two-tiered approach consistent with that recommend-
ed by WHO [11]. Pregnant women with advanced disease (as
indicated by CD4 cell count and WHO stage of disease) were
prescribed HAART and those who did not meet WHO eligibility
criteria were given monotherapy with scZDV as per contemporary
Haitian Ministry of Health guidelines. GHESKIO has published
reports on its success with HAART therapy in both HIV infected
adults and children in urban Haiti [15,16].
Prior to the institution of PMTCT, 60% of the Haitian children
with suspected HIV infection died before six months of age [17].
Other resource-poor settings have also reported a higher and
earlier infant mortality in HIV-1 infected children than seen in the
developed world [18–20]. Although highest in those infants who
are HIV-infected, the excess infant mortality extends to all
children born to HIV-infected mothers. At GHESKIO infant
mortality rate was 200 per 1000 live births in the first 15 months of
life at inception of the program. This rate was similar elsewhere in
Haiti as MTCT programs were being initiated for example-230
per 1000 live births in a rural setting in Mirebalais [21].
In this study, we followed children born to HIV-1 infected
women in the PMTCT program at GHESKIO for their first 15
months of life. The cohort encompassed infants born between
1999 and 2005. Our goals were to: 1) evaluate the program in the
context of its effectiveness in reducing pediatric HIV infection and
increasing survival of infants born to HIV-1 infected women 2) To
identify risk factors for acquiring pediatric HIV and mortality in
the first 15 months of life. Sequential introduction of interventions
over a span of 6 years, gave us the opportunity to identify key
elements of a successful PMTCT program as well as barriers to
effective implementation. Although there is data on the effective-
ness of specific interventions in controlled clinical trials and pilot
projects [22], the present study is unique in being in the context of
implementation of an evolving PMTCT program.
Results
Description of Cohort
Between 1999 and 2005, 551 infants were born to 508 HIV-
infected mothers. There were nine twin deliveries in the cohort.
Each twin was regarded as an individual birth in terms of
outcome. Thirty-four mothers had more than one child during the
period of study, 11 of whom had previously lost a child (and in one
case twins) during the study. Twenty percent of the children had
birth weights #2.5 kg. The majority of infants (85%) were
formula-fed. Forty-five women breastfed and 36 women reported
mixed feeding of breast milk and supplemental foods in the cohort.
Table 1 lists baseline characteristics of the entire cohort and
compares those enrolled before and after the availability of
HAART. Overall, median maternal age was 27 years (inter-
quartile range [IQR] 23–32) and median maternal weight 61
kilograms (kg) (IQR 55–68) at time of enrollment. Nineteen
percent of the women tested were positive for syphilis by rapid
testing. Of the 101 women that were positive by rapid testing, 70
were confirmed by TPHA making the prevalence of syphilis in
HIV-infected women 13%. Median Hgb levels were 9.0 g/dl
(IQR 8–10) at study entry; well below the level recommended by
the WHO for pregnant women ($11.0 g/dl) [23]. The median
CD4 count was 462 cells/mm
3 (IQR 289–686). The clinical stage
of disease was less advanced and there had been fewer prior
deliveries in mothers in the post-HAART era suggesting that less
symptomatic women were presenting for screening and care as the
study progressed. However, their CD4 count on enrollment and
time of presentation during the pregnancy did not change over the
course of the study. Although the percent opting for formula did
not change more infants were exclusively breastfed once HAART
was introduced.
Impact of PMTCT in reducing transmission of HIV-1
Overall HIV infection in infants with sufficient follow-up to
establish a laboratory diagnosis of HIV-status (467 of 551) was
10% (47/467; 95% CI 7.5–13.2). This represents a three-fold
reduction from historically documented levels of 27% [17]. In 22
of the 47 HIV-positive infants the timing of infection could be
determined. Of these 12 were infected in utero (positive test within
72 hours of birth) and 10 were infected peripartum (negative test
at birth but a subsequent positive test). Eighty-four infants had an
undetermined HIV-status due to early death and loss to follow-up.
We compared the transmission rates by ARV regimen used for
prophylaxis. Among the 407 womenreceivingmonovalent ART for
prophylaxis the median duration of therapy was 32 days (IQR 21–
46). The great majority (98%) received scZDV. Only eight received
sdNVP. The overall transmission rate with monovalent therapy was
10.8% (38/353 infants with determined status, Figure 1). Sixty
pregnant women received HAART for a median duration of 61
days (IQR 25–140). Of the 52 infants with final status available only
one infant was HIV-1 infected (1.9%, Figure 1).
Risk factors for MTCT of HIV-1
Univariate analysis on a selected set of parameters showed low
maternal CD4 count, low maternal Hgb, low birth weight, and
female gender to be associated with HIV-1 transmission (Table 2).
Significantly fewer infants were infected among those who had
received complete MTCT therapy (as defined by both maternal
and infant treatment) (Table 2). In multivariate analysis based on
the 421 pairs on which complete data was available only low birth-
weight remained significantly associated with transmission (OR
4.79, 95% CI 2.15–10.67, p=0.0001) when controlling for all
other variables. Relatively few, 81, received breast milk limiting
the power of analyzing the role of feeding choice as risk factor for
transmission.
Impact of PMTCT on Infant Mortality
The overall mortality rate was 15.2 per 100 live births (95% C.I,
12.1–18.8). Twenty-three deaths (27% of the total deaths)
occurred in the first 30 days of life. The mortality rate in children
prior to HAART availability was 0.23 per year followed [0.16–
0.30], and after HAART fell to 0.12 [0.08–0.16], p,0.0001.
Survival improved in both the first 30 days of life and subsequently
up to the 15 month end of follow-up (Figure 2). In the multivariate
model, the availability of HAART was significant after multiple
imputations (p=0.032), (OR, 2.03; [1.06–3.87]), suggesting that
HAART and interventions introduced since 2003 have contrib-
uted to a continued decrease in child mortality seen in both the
2004 and 2005 birth cohorts. Women with live births before
HAART did not differ significantly from women delivering after
HAART in demographics, maternal Hgb level, CD4 counts or
PMTCT in Haiti
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advanced clinical disease and had had fewer prior births (Table 1).
Risk factors for Infant and Neonatal Mortality amongst
HIV exposed infants
A number of factors were predictive of infant mortality by
univariate analysis including infant HIV-1 infection, low birth
weight, maternal syphilis, anemia, low CD4 count, clinical stage of
maternal disease and whether mother was living at 15 months
(Table 3). Completion of PMTCT therapy also associated with
decreased infant mortality (p=0.021). When comparing neonatal
to post-neonatal (31 days–15 months) mortality, the risk factors
that were significantly associated with neonatal mortality were
infant’s HIV-status and maternal syphilis (Table 4). The full
contribution of HIV status to neonatal mortality was hard to
determine as many deaths occurred before a confirmatory PCR
assay could be performed (Table 4). A higher neonatal mortality in
those whose mother had syphilis remains unexplained, particularly
in view of documented single-dose maternal penicillin treatment.
In multivariate analysis performed on 421 with complete data
sets, low-birth weight (Odds Ratio OR, 7.08; [95% CI 3.43–14.58,
P,0.0001] and HIV-status of the infant (OR, 7.74; [2.99–20.03],
P,0.0001) were the only risk factors that remained significantly
associated with infant mortality. After multiple imputations to
account for missing data, maternal stage of disease and maternal
syphilis emerged as additional risk factors.
In our cohort, we found a significant correlation between low
maternal Hgb and low CD4 counts (p,0.001) and HIV positive
status of mother (P,0.01). The effect of an interaction between the
variables was however not statistically significant and did not
Table 1. Cohort comparison before and after the introduction of HAART prophylaxis.
Variable* N
+ Total Pre-HAART Post-HAART p-Value
#
Maternal Demographic Characteristics
Age, Median (IQR), years 547 27.0 (23.0–32.0) 28 (23–33) 27 (23–31) 0.30
2
Weight, Median (IQR), kg 512 60.8 (55.4–67.7) 62 (56–68) 60 (54–67) 0.15
2
Parity, Mean 490 1.7 2.5 1.3 ,0.001
2
Gestation at entry, Mean, mths 547 5.4 5.5 5.3 0.34
2
Maternal Clinical Characteristics
CD4 count, Median (IQR), cell/ul 515 462.0 (289.5–686.0) 460 (314–730) 462 (284–664) 0.30
2
Baseline Hgb levels, Median (IQR) 469 9 (8–10) 9 (8–10) 9 (8–10) 0.32
2
Maternal stage of disease 526 ,0.001
1
Asymptomatic 335 (60) 103 (49.5) 232 (73)
Symptomatic 58 (11) 20 (9.6) 38 (12)
Clinical stage AIDS 133 (24) 85(41) 48 (15)
Maternal Syphilis 543 0.40
1
Positive 101 (19) 44 (21) 57 (17)
Negative 442 (81) 172 (80) 270 (83)
Maternal Death 508 0.21
1
Alive 483 (95) 189 (93) 294 (96)
Death 25 (5) 14 (7) 11 (4)
Infant Characteristics 0.38
1
HIV Status of Infant 467
Negative 420 (90) 160 (88) 260 (91)
Positive 47 (10) 21 (12) 26 (9)
Gender 551 0.41
1
Female 284(52) 116(54) 168(50)
Male 267(48) 100(46) 167(50)
Birth weight 491 0.34
1
.2.5 Kg 395(80) 161(83) 234(79)
#2.5 kg 96(20) 34(17) 62(21)
Feeding 551 ,0.001
1
Formula 469(85) 183(85) 286(86)
Breast-fed 46(8.3) 9(4) 37(11)
Mixed 36(6.5) 24(11) 12(4)
Infant death ,15mths 551 84(15) 46(21) 38(11) 0.002
1
*Unless otherwise indicated, data are presented as number (%)
+Number for whom data was available
#Difference between Pre-HAART and Post-HAART cohort using:
1 Pearson’s chi-square test;
2 Wilcoxon Test
doi:10.1371/journal.pone.0003723.t001
PMTCT in Haiti
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predict mortality with a p,0.0001.
Discussion
We report success in using both single drug short course
regimens and a two-tiered approach in which HAART is
prescribed for women with advanced disease as per WHO criteria
and single drug regimens are given to all others. Mothers enrolled
between 1999–2003 received only scZDV or sdNVP. In 2003,
HAART became available in Haiti and mothers enrolled from
March, 2003 until the end of the current analysis (infants born
through December, 2005) received either scZDV, sdNVP or
HAART as indicated by CD4 cell count and clinical staging. To
date there have been few reports on the safety and effectiveness of
HAART in HIV-infected pregnant women in low-resource
countries though such a 2-tiered program has been suggested as
a means to gain maximum impact of PMTCT [13,24].
Impact of PMTCT in reducing transmission of HIV-1
The reduction in transmission is encouraging considering that
35% of the women received less than the recommended duration
of therapy and 15% no prophylaxis at all. Furthermore, these
estimates may represent upper limits as adherence to therapy was
not assessed pharmacologically and self-reporting has been shown
to be subject to bias [25,26].
Although reduced from historical controls transmission rate in
the cohort of women given exclusively single drug prophylaxis
versus those that were part of the two-tiered program (either ZDV
or HAART if indicated) was similar (12% versus 9.1%). However,
in 60 women who received HAART transmission rate was 1.9%,
similar to that seen in developed countries suggesting that
prophylaxis with HAART alone where possible would be more
effective than monotherapy. No comparison of HAART with dual
therapy or more prolonged monovalent therapy can be inferred
from this trial and in that respect emphasizes the need to look
comprehensively at the optimal approach to PMTCT in the
developing country setting.
Impact of PMTCT on Infant Mortality
Children born to HIV-1 infected mothers are at increased risk
of mortality [19]. Infant mortality prior to the introduction of
antiretrovirals for prevention of MTCT was 23 per 100 live births
[17] and it continued at that rate through the first three years of
Figure 1. Profile of Cohort. Population used to estimate rate of mother-to-child transmission of HIV in the GHESKIO PMTCT program in Port-au-
Prince, Haiti between March 1999 through December 2005. Cohort is divided based on the date of initiation of HAART for both individual health and
PMTCT. Among the 47 HIV-infected infants, 38 had received scZDV alone, eight had received no-prophylaxis and 1 had received HAART.
doi:10.1371/journal.pone.0003723.g001
PMTCT in Haiti
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through the period coincident with the introduction of HAART
and was seven per 100 in the year 2005. Although more women
having clinical AIDS in the pre-HAART cohort could have
contributed to the worse prognosis of the infants, in multivariate
analysis reduced mortality in infants born post-HAART remained
significant even when adjusted for maternal stage of disease.
As has been demonstrated in earlier studies, low birth weight
and infant HIV-status emerged as significant risk factors for infant
mortality [27,28]. A recent study from West Africa (MTCT-Plus
Initiative) observed a higher proportion of low birth weight in
neonates receiving HAART versus simplified regimens [13,29]
raising the possibility that HAART may have contributed to the
low birth weight. We did not observe an increased number of low
birth weight infants born to women receiving HAART for
prophylaxis. A high percentage of the infant mortality occurred
in the first month of life. Surprisingly the neonatal mortality was
not disproportionately due to low birth weight.
The difference in mortality rate before and after HAART
introduction (p,0.0001) and the reduction in HIV MTCT though
impressive occurred in the face of a changing population
presenting to GHESKIO and was only a part of what has become
an integrated and comprehensive maternal and child care
programs. For example, beginning 2001, co-trimoxazole was
introduced for all HIV-exposed infants in the PMTCT program
beyond 6 weeks of age. Co-trimoxazole prophylaxis has proven to
be a cost-effective intervention with demonstrated success in
increasing infant survival in both African settings [30,31] and at
GHESKIO [32]. Vaccination with pneumococcal vaccine and
conjugated H. influenzae was also begun in 2001. Both of these
interventions preceded the observed decline in mortality in 2004
and 2005.
Role of Feeding in Transmission and Mortality
There is a consensus emerging that exclusive breastfeeding is
the most viable option in resource-limited settings for survival of
Table 2. Risk factors associated with transmission of HIV-1 from mother to infant.
Variable* N Negative n=420 Indeterminate n=84 Positive n=47 p -Value
Prophylaxis (Mother+Infant)
a 0.016
1
None 84 54 (64) 22 (26) 8 (9.5)
Incomplete 194 145 (74) 31 (16) 18 (9.3)
Complete 273 221 (81) 31 (11) 21 (7.7)
Stage of Maternal Disease 0.067
1
Asymptomatic 335 264 (79) 48 (14) 23 (7)
Symptomatic 58 42 (72) 13 (22) 3 (5)
Aids 133 93 (70) 22 (16) 18 (13)
Missing 25 21 (84) 1 (4) 3 (1.2)
Maternal Syphilis 0.39
1
RPR Positive 101 71 (70) 21 (21) 9 (9)
RPR Negative 442 344 (78) 61 (14) 37 (8)
Missing 8 5 (62) 2 (25) 1 (20)
Maternal CD4 counts
+ 515 480 (322–745) 404 (243–585) 409 (284–578) 0.004
2
Maternal Hgb values
+ 469 9.2 (8.5–10.1) 9.0 (7.7–10.0) 9.0 (8.0–10.0) 0.002
2
Birth weight ,0.001
1
.2.5 kg 395 325 (82) 47 (12) 23 (6)
#2.5 kg 96 58 (60) 22 (33) 16 (17)
Gender 0.02
1
Female 284 203 (71) 50 (18) 31 (11)
Male 267 217 (81) 34 (13) 16 (6)
*Continuous variables (
+) represented as median value (IQR), all others as frequencies (%, calculated by row.
aSixty received HAART, eight received sd-NEV, rest received monotherapy with AZT.
1Pearson’s chi-square test;
2 Kruskal-Wallis test
doi:10.1371/journal.pone.0003723.t002
Figure 2. Mortality Pre and Post the availability of HAART. The
overall reduction in mortality is significant and extends to both the
neonatal and infant age ranges.
doi:10.1371/journal.pone.0003723.g002
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not associated with a change in HIV-1 transmission or neo-natal
and post neonatal mortality (data not shown) we were severely
limited in power to make any meaningful conclusions as 85% of
women chose to formula-feed. Regardless of mode of feeding,
complementary food introduced to infants beyond six months of
age must be of adequate caloric and nutritional value to ensure
continued growth. Recognizing that growth faltering occurs after
weaning from formula or breastfeeding, a nutritional intervention
study is underway at GHESKIO.
Lessons learned and new directions for the future
In addition to the factors identified by multivariate analysis, low
birth weight and infant HIV status, the variables identified as
significant by univariate analysis deserve consideration when
developing models for monitoring progress and program improve-
ment. For instance maternal syphilis and anemia are areas that
with remedial action could positively impact the effectiveness of
the program. The high percentage of HIV-infected pregnant
women with syphilis certainly reinforces the need to integrate
testing for both syphilis and HIV to all women.
Our study was limited in that it was not a randomized
intervention study. Anticipating the rapid evolution of PMTCT
practice during this period we employed components of a
continuous quality improvement model in a programmatic setting.
As a result, we were unable to dissect the effects of individual
interventions (such has HAART for mothers versus co-trimoxazole
for infants). Additionally, only 421 of mother-infant pairs (out of
551) have non-missing data for all risk factors reducing the power
of the multivariate analysis. Finally the unknown HIV infection
status of the 84 infants who died or were otherwise lost to follow-
up may have altered the transmission frequency and risk factors in
ways that we cannot predict. Never-the-less the 7.2% lost to
follow-up rate (after exclusion of the 42 early deaths) seems low in
a country with the high level of social disruption currently seen in
Haiti.
This study demonstrates how rigorously analyzed data in
PMTCT programs can be used to make evidence-based decisions.
With risk factors better defined by this and other papers a
prospective, comprehensive examination of risk factors for pre-,
peri- and postnatal HIV transmission and improvement of infant
survival could have a major impact on one of our most successful
interventions to reduce the impact of HIV.
In conclusion, we analyzed the data collected over six years in a
PMTCT program established in resource-limited Haiti to answer
whether: 1) the current practices within the PMTCT program are
Table 3. Risk factors associated with infant mortality
Variable* N Infant Alive n=467 Infant Died n=84 p-Value
1
Prophylaxis (Mother+Infant) 0.026
None 84 63(75) 21(25)
Incomplete 194 168(87) 26(13)
Complete 273 236(86) 37(14)
Maternal Status 0.021
Alive 521 446(86) 75(14)
Dead 30 21(70) 9(30)
Stage of Maternal Disease ,0.001
Asymptomatic 335 300(90) 35(10)
Symptomatic 58 47(81) 11(19)
Aids 133 98(74) 35(26)
Maternal Syphilis 0.008
RPR Positive 101 76(75) 25(25)
RPR Negative 442 385(87) 57(13)
Unknown 8 6(75) 2(25)
Maternal CD4 counts
+ 515 474(302–710) 384(242–552) ,0.001
2
Maternal Hgb values
+ 469 9.4(8.4–10.1) 9(8–10) ,0.001
2
Infant HIV Status ,0.001
Negative 420 395(94) 25(6)
Indeterminate 84 43(51) 41(49)
Positive 47 29(62) 18(38)
Gender 0.021
Female 284 231(81) 53(19)
Male 267 236(88) 31(12)
Birth weight ,0.001
.2.5 kg 395 357(90) 38(10)
#2.5 kg 96 56(58) 40(42)
*Continuous variables (
+) represented as median value (lower quartile-upper quartile), all others as frequencies (%, by row).
1Pearson’s chi-square test unless otherwise indicated;
2 Wilcoxon Test
doi:10.1371/journal.pone.0003723.t003
PMTCT in Haiti
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identify risk factors for transmission and mortality that will guide
future interventions. We find in the Haitian setting that with the
introduction of HAART can limit transmission to levels that
approach those in industrialized countries. However, early infant
mortality continues to be observed in HIV-1 exposed children
suggesting that factors such as maternal anemia, prevention of low
birth weight infants are important areas of investigation.
Challenges remain in enhancing coverage and devising mecha-
nisms to assure early presentation in pregnancy and compliance.
Finally, we have demonstrated the ability of PMTCT programs to
adopt complicated anti-retroviral regimens with success despite
limited human resources and anticipate with expanded coverage
of HAART in a comprehensive maternal-infant program
continued gains in coming years.
Methods
PMTCT Model and Clinical Care of Participants
The GHESKIO Centers located in Port-au-Prince, Haiti
provide VCT services for over 26,000 individuals yearly and care
for the approximately 15% of those who are HIV infected. The
comprehensive program integrates VCT with reproductive health
(family planning), treatment for sexually transmitted disease,
diagnosis and therapy of tuberculosis and pre- and post-natal
care for HIV-infected mothers and their infants. The GHESKIO
model has been previously described [35]. The PMTCT services
provided within the comprehensive program serve as a laboratory
for the Ministry of Health to inform national recommendations for
HIV care.
The participants in this study included all available HIV-
infected pregnant women and their live-born infants enrolled
between March 1999 and December 2005 and followed until 15
months of age and/or a diagnosis of pediatric infection with HIV
could be made. All HIV-infected pregnant women were
individually counseled, informed of their HIV status, and referred
to the antenatal clinic where a series of regular prenatal visits with
the obstetrical team were scheduled. An agreement was signed by
the women to participate in the provision of services at GHESKIO
and to allow the physicians to review their records. The activities
were reviewed by the GHESKIO IRB and deemed to be provision
of services.
Antenatal Care and Antiretroviral Regimens. At the
onset of the pilot program (March 1999) scZDV was made
available to every HIV-infected pregnant woman with a
hemoglobin (Hgb) level .8.5 g/dl before or at an estimated 36
Table 4. Univariate analysis comparing early and late infant mortality
Variable* N
Neonatal mortality
(#30 days) n=23
Post-neonatal mortality
(31–450 days) n=61 p-Value
1
Prophylaxis (Mother+ Infant) 0.16
None 84 4(5.0) 17(20)
Incomplete 194 5(2.6) 21(11)
Complete 273 14(5.1) 23(8.4)
Maternal Status 0.71
Alive 521 21(4.0) 54(10)
Dead 30 2(7.0) 7(2.3)
Stage of Maternal Disease 0.51
Asymptomatic 335 8(2.4) 27(8.0)
Symptomatic 58 3(5.2) 8(14)
Aids 133 12(9.0) 23(17)
Maternal Syphilis 0.04
RPR Positive 101 11(11) 14(14)
RPR Negative 442 12(3) 45(10)
Maternal CD4 counts
+ 79 480(230–552) 372(249–541) 0.9
2
Maternal Hgb values
+ 77 8(8–10) 9(8–10) 0.72
2
Infant HIV status 0.048
Negative 420 7(2.0) 18(4.3)
Indeterminate 84 15(18) 26(31)
Positive 47 1(2.0) 17(36)
Gender 0.8
Female 284 14(5.0) 39(14)
Male 267 9(3.3) 22(8.2)
Birth weight 0.29
.2.5 kg 395 11(2.8) 27(7.0)
#2.5 kg 96 12(12.5) 28(29)
*Continuous variables (
+) represented as median value (lower quartile-upper quartile), all others as frequencies (%, by row).
1Pearson’s chi-square test unless otherwise indicated;
2 Wilcoxon Test
doi:10.1371/journal.pone.0003723.t004
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every 3 hours until delivery)[8,36,37]. Women who presented for
care close to time of delivery or had Hgb below 8.5 g/dl were
instructed to self-administer a single dose (sd) of 200 mg of NVP at
the onset of labor. Beginning in March 2003, pregnant women
with clinical indications or with a CD4 count of ,350 cells/dL
were administered zidovudine/lamivudine/nevirapine (ZDV/
3TC/NVP) or, if the mother was anemic, stavudine/
lamivudine/nevirapine (d4T/3TC/NVP). Treatment was started
for maternal health, and continued through pregnancy and after
delivery. Pregnant women not eligible for HAART continued to
receive prophylaxis that included either scZDV or sdNVP. All
infants were started on ZDV at 2 mg per kilogram every six hours
for seven days irrespective of maternal drug regimen. Compliance
to therapy was monitored through self-reporting, pill counts and
pharmacy records. Prenatally, mothers were counseled on infant
feeding options. They were given the choice between formula,
(provided at no cost for the first nine months) and breastfeeding.
Women who chose not to breastfeed were instructed on
preparation of formula, safe sources of water, and oral
rehydration.
Virtually all deliveries occurred vaginally in a home setting
accompanied by a traditional birth attendant [38]. Mothers or
other family members were encouraged to bring infants to the
clinic within three days of life at which point infants were started
on ZDV at 2 mgm/kg every six hours for seven days.
Follow-up. Visits were scheduled for mother and infant twice
a month for six months and then once a month until 24 months of
age. Infants were provided trimethoprim-sulfamethozaxole (co-
trimoxazole) (150 mg/m
2/24 hours for three consecutive days per
week) beginning at six weeks of life following recommendations
[32,39]. Since 2003, infants diagnosed with HIV infection have
been started on HAART based on WHO criteria [16]. Routine
immunizations in the Expanded Program on Immunization for
Haiti were provided as well as unconjugated pneumococcal and
conjugated haemophilus influenzae vaccines from 2001.
At each visit, the infant was weighed and sufficient formula
given to provide nutrition until the next visit. Permission was
requested to make home visits (one field worker assigned for 50
women) if the women did not return for their recommended visits.
Children were considered lost to follow-up if they did not visit for a
period of three months and could not be located by the field
worker.
Laboratory
Maternal Testing. Rapid whole blood HIV antibody testing
was done using Determine HIV 1/2 (Abbott Laboratories, Abbot
Park IL) and Capillus HIV 1 and 2. (Trinity Biotech, Bray,
Ireland) [40,41]. The diagnosis of HIV infection was dependent on
both results being positive. If the results of the results were
discrepant, the laboratory performed a Western Blot for final
designation of HIV status. Routine syphilis was done using Rapid
Plasma Reagin (RPR; Becton Dickinson, Sparks, MD) with
confirmation by FTA-ABS. Women with syphilis were treated
and their infants treated as indicated based on the completeness of
maternal therapy. CD4 cell counts are determined by flow
cytometry using FACSCount (Becton Dickinson Biosciences, San
Jose, CA). Hgb values were determined using a Coulter counter
(Beckman Coulter Inc, Miami, FL). In some cases data entry was
by integers and the complete value to the first decimal point could
not be retrieved.
Infant HIV status. HIV infection in children born of HIV-
infected mothers was determined by a nucleic acid sequence-based
assay, NASBA (bioMerieux Boxtel, The Netherlands) for the first 3
years of the study. Since that time, polymerase chain reaction
(PCR) testing for HIV-1 RNA (COBAS AMPLICOR, Roche
Molecular Diagnostics, Branchburg, NJ) has been performed on
HIV-exposed infants at birth, 2–3 months and six months of age.
Both have cut-off values of 400 copies/ml. In 2003, a simplified
p24 antigen assay was introduced for early diagnosis of infant
HIV-1 infection [42]. HIV antibody test (ELISA) was repeated
every three months until seroreversion confirmed that maternal
antibodies had disappeared. Criteria for determining infant HIV
status were based on serology and nucleic acid detection as
previously described [32]. Clinical criteria did not enter into the
determination of HIV status.
Definitions and Measurement of Risk Factor Variables
Maternal CD4 counts and Hgb values were examined from
enrollment, during pregnancy and within three months after
delivery. For this analysis, we used the CD4 measurement closest
to the date of delivery and the earliest Hgb obtained in the course
of the pregnancy.
Women within our cohort received one of three regimens:
scZDV, sdNVP or HAART. Complete maternal treatment was
defined as receiving 28 days of scZDV antepartum or sdNVP at
the onset of labor. As HAART regimens included NVP, women
receiving less than 28 days of HAART before delivery were
considered to have completed their prophylaxis. Infant treatment
was complete if the infant received one week of ZDV started
within 72 hours of birth. Prophylaxis for PMTCT was considered
complete only if both the mother and infant received the
recommended duration of therapy, based on a combination of
pharmacy records and self-reporting by the women.
Maternal and infant deaths were defined as deaths occurring
within 15 months after delivery. Because infant deaths in the first
month of life are often attributable to perinatal events these were
separately analyzed. Birth weight of the infant was deemed to be
the first available measurement within 14 days from birth as
weights do not generally change dramatically from birth weight
during that time.
An infant with a positive PCR within three days of life was
classified as infected in utero. An infant with a negative PCR at
birth but subsequently confirmed to be HIV positive was
considered to have been infected in the peripartum or potentially
through breast milk if that had been offered. All others who were
HIV positive but not assignable to in utero or peripartum infection
because of lack of early PCR were scored as infected but with
uncertainty as to timing and route of infection [43].
To capture the effectiveness of transition from limited to more
complete prophylactic regimens and interventions, we divided the
cohort based on date of initiation of HAART in March of 2003.
All women prior to that date received only scZDV or sdNVP.
Women in the later portion of the cohort received either HAART,
scZDV or sdNVP based on CD4 counts and clinical stage.
Statistical Analysis
Analysis of all data presented in this manuscript was handled
with patients being de-identified. All clinical, demographic and
laboratory data on mothers and their infants were incorporated
into an integrated data management system. Univariate analysis,
to assess covariates as predictors of transmission and infant
mortality were performed using Chi-square test for category
variables, and Wilcoxon rank-sum/Kruskal-Wallis test for contin-
uous variables.
Multivariable logistic regression models were performed on
mother-infant pairs that had complete data for all risk factors
included. One model, utilized HIV-status of the infant as the
PMTCT in Haiti
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in the models were: HIV status of infant, low birth weight,
maternal death within 15 months from infant birth, treatment
status, maternal Hgb, maternal clinical stage of disease, maternal
syphilis, breast milk exposure and whether enrolled before first
HAART date or after. In a separate analysis missing values for risk
factors in the multiple regression models were imputed using the
flexible semiparametric algorithm in Hmisc package in R [44]
(http://cran.rproject.org/web/packages/Hmisc/index.html).
Interaction effects between birth weight and other risk factors
were tested with a single global (pooled) test and were not
significant. Therefore, interaction terms were not included in the
models.
Mortality rate per year of follow-up was defined as the number
of deaths divided by the follow-up time (censored at 15 months),
and 95 percent confidence intervals were calculated with the use of
Poisson distribution. Comparison of rates was based on normal-
theory test. Proportions of transmission by treatment status were
reported and the 95 percent confidence intervals were computed
with the use of the binomial distribution. All calculations were
done using R version 2.6 (software available at www.r-project.org).
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